A Phase 4 interventional study of Intravenous furosemide bolus injections and ACETAZOLAMIDE oral capsule in Acute Heart Failure (AHF), sponsored by Lucrecia Maria Burgos. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Lucrecia Maria Burgos · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.
Among the 14 studies testing acetazolamide in Heart Failure, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 4, and was the 12th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Johannes Grand · Sites in Denmark
Ages 18+
Universitas Diponegoro · Sites in Indonesia
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Clinica Alemana de Santiago
Ages 18+
By country, each count listing its studies:
Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 14 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Lucrecia Maria Burgos as lead sponsor.
Lucrecia Maria Burgos has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies testing acetazolamide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593612Lucrecia Maria BurgosTACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure | 2027-01-15 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT06273397Clinica Alemana de SantiagoAcetazolamide or Metolazone in Acute Heart Failure | 2027-03-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing acetazolamide in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.
Participants will receive sequential treatment with:
The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety.
Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.
The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.
Heart failure congestion remains one of the leading causes of hospitalization and recurrent healthcare utilization worldwide. Although loop diuretics represent the cornerstone of decongestive therapy, many patients develop suboptimal diuretic response or diuretic resistance during the course of chronic heart failure.
Sequential nephron blockade strategies combining loop diuretics with agents acting at different tubular sites may enhance natriuresis and improve decongestion. Recent inpatient studies have suggested potential benefits of acetazolamide- and thiazide-based strategies; however, evidence regarding ambulatory worsening heart failure management remains limited.
TACTIC-HF is a prospective, single-center, randomized, open-label crossover trial evaluating three commonly used outpatient decongestion strategies in patients with worsening heart failure treated in a dedicated heart failure day-hospital setting.
Participants will sequentially receive:
Treatments will be administered during structured outpatient sessions with standardized monitoring and predefined washout intervals between treatment periods.
The primary endpoint is total urinary sodium excretion during the treatment session. Secondary endpoints include urine output, congestion-related parameters, and renal/electrolyte safety outcomes.
The study is designed as a pragmatic trial using approved therapies routinely available in clinical practice, with the objective of generating physiologically oriented evidence applicable to ambulatory heart failure care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive outpatient intravenous furosemide according to the study protocol during a structured ambulatory treatment session.
Drug: Intravenous furosemide bolus injections
Participants receive outpatient intravenous furosemide combined with oral acetazolamide during a structured ambulatory treatment session
Drug: Intravenous furosemide bolus injections · Drug: ACETAZOLAMIDE oral capsule
Participants receive outpatient intravenous furosemide combined with oral hydrochlorothiazide during a structured ambulatory treatment session
Drug: Intravenous furosemide bolus injections · Drug: Hydrochlorothiazide (HCT)
Intravenous loop diuretic therapy administered during outpatient treatment sessions according to protocol-defined dosing categories.
Oral acetazolamide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions
Oral hydrochlorothiazide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions.
Total Urinary Sodium Excretion at 6 Hours
Total urine volume collected during the outpatient treatment session
Time frame: 6 hours
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.
Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 7 months is below that.
Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetazolamide · Hydrochlorothiazide